Seven of the eight confirmed responders within the EOC, TNBC and NSCLC expansion cohorts had LAG-3 expression at baseline, and half (n = 4) were PD-L1+ (Extended Data Fig. 4a). The gene discussed is LAG3; the disease is non-small cell lung carcinoma.